Could two old drugs beat long COVID? new trial aims to find out
NCT ID NCT06974084
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether two FDA-approved drugs, maraviroc and atorvastatin, can help people with Long COVID. 252 adults aged 18-65 with persistent symptoms will take either the drug combination or a placebo for 16 weeks. The main goal is to see if it reduces fatigue and improves physical and mental function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Maraviroc and Atorvastatin
- What this could lead to
- If it works, this could point toward a treatment for Long COVID symptoms like fatigue and brain fog using already-approved drugs.
- What could go wrong
- This is a Phase 2/3 trial, so it's still early. The drugs are not yet proven for Long COVID, and there is a chance they won't work better than placebo. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Arizona
Tucson, Arizona, 85719, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Could exercise retrain the heart in long COVID?
- Can brain games and gentle currents lift long COVID brain fog?
- Brain fog after COVID: can a mental workout restore focus?
- Can brain training zap long COVID brain fog?
- Ear device zaps vagus nerve in bid to quiet long COVID fatigue and brain fog